Published in BMJ on August 28, 2004
Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA (1986) 7.23
Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA (2003) 6.17
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med (2004) 3.49
Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest (1996) 3.13
Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet (2004) 2.45
Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol (2000) 2.10
Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol (2002) 2.07
Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J (2004) 1.41
Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation (2000) 1.28
Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol (1997) 1.25
Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res (1992) 1.03
Coronary calcification score: the coronary-risk impact factor. Lancet (2004) 0.99
Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol (2004) 0.97
Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome. Obes Res (2003) 0.92
Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. Clin Sci (Lond) (2003) 0.81
Measurement of the reflectivity of the intima-medial layer of the common carotid artery improves the discriminatory value of intima-medial thickness measurement as a predictor of risk of atherosclerotic disease. Ultrasound Med Biol (2007) 0.79
Coronary calcification and predicted risk of coronary heart disease in asymptomatic men with hypercholesterolaemia. J Cardiovasc Risk (2002) 0.79
Comparison of efficacy of plant stanol ester and sterol ester: short-term and longer-term studies. Am J Cardiol (2005) 0.79
Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr Atheroscler Rep (2015) 0.78
Normal levels of inflammatory markers in treated patients with familial hypercholesterolaemia: a cross-sectional study. JRSM Cardiovasc Dis (2012) 0.75
New developments in pharmacotherapy. Cardiovasc J S Afr (2004) 0.75
Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis. J Thromb Thrombolysis (2008) 0.75